BLBAUPOST GROUP LLC/MA
Institutional investor · Portfolio as of Q2 2020
Top Holdings31 positions
EBAY INC. | 32.1M | $1.7B | 21.0% | $28.26 | +65.38% | 7 qtrssince 2018-Q4 | Unchanged 0 |
LIBERTY GLOBAL PLC | 54.6M | $1.2B | 14.6% | — | — | 7 qtrssince 2018-Q4 | Increased 64 |
FOX CORP | 27.3M | $732.8M | 9.1% | $33.43 | -25.22% | 6 qtrssince 2019-Q1 | Unchanged 0 |
VIASAT INC | 13.7M | $526.9M | 6.6% | $58.03 | -32.22% | 7 qtrssince 2018-Q4 | Unchanged 0 |
PARAMOUNT GLOBAL | 18.8M | $439.3M | 5.5% | — | — | 3 qtrssince 2019-Q4 | Decreased 0 |
QORVO INC | 3.1M | $338.8M | 4.2% | $62.94 | +70.69% | 7 qtrssince 2018-Q4 | Increased 58 |
Telesis Bio, Inc. | 18M | $319.1M | 4.0% | — | — | 7 qtrssince 2018-Q4 | Increased 59 |
HP INC | 18M | $313.8M | 3.9% | $15.66 | -9.32% | 3 qtrssince 2019-Q4 | Decreased 0 |
ALPHABET INC | 214,680 | $303.5M | 3.8% | $57.60 | +21.57% | 2 qtrssince 2020-Q1 | Decreased 0 |
MCKESSON CORP | 1.7M | $256.1M | 3.2% | $112.57 | +30.21% | 7 qtrssince 2018-Q4 | Unchanged 0 |
HD SUPPLY HLDGS INC | 6.6M | $229.4M | 2.9% | — | — | 2 qtrssince 2020-Q1 | Increased 57 |
AKEBIA THREAPEUTICS INC | 15M | $203.7M | 2.5% | $5.39 | -84.88% | 7 qtrssince 2018-Q4 | Decreased 0 |
THERAVANCE BIOPHARMA INC | 9.3M | $195.4M | 2.4% | $23.43 | -11.91% | 7 qtrssince 2018-Q4 | Unchanged 0 |
META PLATFORMS INC | 851,500 | $193.4M | 2.4% | $164.80 | +32.96% | 2 qtrssince 2020-Q1 | Decreased 0 |
NEXSTAR MEDIA GROUP INC | 2.1M | $174.5M | 2.2% | $71.98 | -2.50% | 7 qtrssince 2018-Q4 | Unchanged 0 |
LIBERTY GLOBAL PLC | 7.7M | $167.4M | 2.1% | — | — | 7 qtrssince 2018-Q4 | Unchanged 0 |
FOX CORP | 5.7M | $152.5M | 1.9% | $32.49 | -23.79% | 6 qtrssince 2019-Q1 | Unchanged 0 |
Atara Biotherapeutics, Inc. | 9.9M | $144.6M | 1.8% | — | — | — | Increased 57 |
HCA HEALTHCARE INC | 1M | $97.1M | 1.2% | $91.93 | +384.07% | 1 qtr | New 69 |
COLONY CAP INC NEW | 25.7M | $61.7M | 0.8% | — | — | 7 qtrssince 2018-Q4 | Decreased 0 |
BAUPOST GROUP LLC/MA manages $8B across 31 positions as of Q2 2020. Top holdings: EBAY (21.0%), LBYKV (14.6%), FOXA (9.1%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 4.5/5.0.
Active quarter - 4 new positions, 6 exits, 5 increased. Top move: HCA (NEW, conviction 69). Portfolio: $8.0B across 31 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR